<DOC>
	<DOCNO>NCT01700790</DOCNO>
	<brief_summary>The object study evaluate pharmacokinetic interaction , short term safety efficacy standard dose lopinavir/ritonavir 200mg/50 ( two tablet twice daily ) give ritonavir 100 mg three tablet twice daily give combination rifampin HIV-infected person tuberculosis</brief_summary>
	<brief_title>Pharmacokinetic Study Super-boosted Lopinavir/Ritonavir Given With Rifampin</brief_title>
	<detailed_description>This open label non-randomized pharmacokinetic study 10-12 HIV-infected patient co-infected Mycobacterium tuberculosis . Enrollment : Potential subject active tuberculosis tolerate rifampin contain regimen least 2 week . Potential subject refer surround community Laboratorio de Pesquisa Clinica em Micobacterioses ( LAPCLINTB ) Visit 1 : Subjects start lopinavir/ritonavir contain HAART regimen standard twice daily dose . Ritonavir 100 mg capsule add regimen dose escalate patient take 3 capsule twice daily . The time enrollment visit 1 determine treat physician . Visit 2 : They return 1 week dose escalation complete sample lopinavir rifampin concentration . Visit 3 : Subject return 2 week repeat review result lopinavir concentration response therapy . Ritonavir adjust need . Visit 4 : Subject return 4 week last visit evaluation . Lopinavir rifampin PK do .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Antiretroviral naive If antiretroviral na√Øve must meet following criterion : Taking Kaletra contain regimen suppress viral load . Taking NNRTI integrase contain regimen without prior history use PI 2 week Taking NNRTI integrase contain regimen prior exposure PI great 2 week . It must clearly state source document PI switch another agent convenience . Taking another PI contain regimen suppress viral load . It must clearly state source document another PI use great 2 week regimen switch another agent convenience . Subjects prior history PI use may enrol , genotype show resistance Kaletra Other Inclusion criterion Be least 18 year age able give inform consent . Diagnosed TB criterion per Brazilian Ministry Health Have good clinical response TB . Tolerating tuberculosis therapy contain rifampin 2 week prior screen , except person take protease inhibitor time diagnosis TB. , . Subjects take protease inhibitor screen initiate visit 1 within 3 day start TB medication HIV positive documentation present source document . Have CD4 cell count great 50 cells/mm3if take ART . Persons cd4 &lt; 50 may enrol , felt best interest patient , enrollment study allow quicker initiation antiretroviral therapy referral another treatment center . Noncompliance DOTPlus . Alternatively DOT do telephone patient daily basis 5 time week patient annotate take drug log would review clinic staff History treat tuberculosis prior 2 year unless DST , include PCR testing , show sensitivity rifamycin . Known hypersensitivity rifampin rifabutin . Liver enzymes great 2 time ULN . Bilirubin great 2 time ULN . Serum creatinine great 3 time ULN . Hemoglobin le 7.0 gm even receive erythropoietin . Absolute neutrophil count le 750 cells/mm3 even receive GCSF . Fasting triglyceride great 400 mg/dL . Fasting cholesterol &gt; 1.6 upper limit normal . GI intolerance tuberculosis medication require discontinuation tuberculosis medication . Fasting glucose great 150 mg/dL . Pregnant woman . Use one prohibited medication Any condition investigator feel could compromise use current medication . Have CD4 cell count 50 cells/mm3or less Hepatitis B C infection Alcohol illicit drug use , investigator opinion may affect participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Rifampin</keyword>
	<keyword>Lopinavir</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>